Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance

USP7 is a promising target for the development of cancer treatments because of its high expression and the critical functions of its substrates in carcinogenesis of several different carcinomas. Here, we demonstrated the effectiveness of targeting USP7 in advanced malignant cells showing high levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Sol-Bi, Kim, Chang-Hyeon, Jang, Hay-Ran, Yim, Hyungshin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697005/
https://www.ncbi.nlm.nih.gov/pubmed/33207738
http://dx.doi.org/10.3390/ijms21228629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697005/
https://www.ncbi.nlm.nih.gov/pubmed/33207738
http://dx.doi.org/10.3390/ijms21228629

Ejemplares similares